Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Recursion Pharmaceuticals Inc
RXRXCurrent price
6.32 USD
-0.64 USD (-9.20%)
Last closed
6.88 USD
Company
www.recursion.com
ISIN
US75629V1044
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 893 713 664 USD
Yield for 12 month
-41.26 %
1Y
3Y
5Y
10Y
15Y
RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Address: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
9.86 USDP/E ratio
–Dividend Yield
–Current Year
+44 575 000 USD
Last Year
+39 681 000 USD
Current Quarter
+26 082 000 USD
Last Quarter
+14 417 000 USD
Current Year
+1 988 000 USD
Last Year
-8 594 000 USD
Current Quarter
+14 003 000 USD
Last Quarter
+1 318 000 USD
Key Figures RXRX
1 year
3 years
5 years
10 years
EBITDA
-364 150 016 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-36.40 %
PEG Ratio
–
Return On Equity TTM
-78.49 %
Wall Street Target Price
9.86 USD
Revenue TTM
65 184 000 USD
Book Value
1.83 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
147.60 %
Dividend Yield
–
Gross Profit TTM
-164 128 000 USD
Earnings per share
-1.54 USD
Diluted Eps TTM
-1.54 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RXRX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History RXRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation RXRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
39.58
Price Sales TTM
44.39
Enterprise Value EBITDA
-5.31
Price Book MRQ
5.52
Financials RXRX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RXRX
For 52 weeks
5.60 USD
15.74 USD
50 Day MA
6.72 USD
Shares Short Prior Month
64 573 303
200 Day MA
7.91 USD
Short Ratio
7.59
Shares Short
67 845 763
Short Percent
19.03 %
BeatStart